查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594130

偏头痛药物市场：依治疗层级、治疗类型、给药途径、分布 - 全球预测 2025-2030

Migraine Drugs Market by Therapeutic Class (Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots), Treatment Type (Abortive, Preventive), Route of Administration, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年偏头痛治疗药物市场价值为47.4亿美元，预计到2024年将达到54.8亿美元，复合年增长率为15.83%，预计到2030年将达到132.6亿美元。

偏头痛药物市场范围包括用于治疗急性和慢性偏头痛的药物，其应用范围从预防到流产治疗。该市场的驱动因素是解决影响全球生产力和生活品质的各种神经病变的需求。曲坦类、降钙素基因相关胜肽抑制剂和非处方药等处方药占其应用的大部分，最终用途是医疗机构、药房和个别患者。偏头痛发病率的增加、药物配方的进步以及患者和医疗保健专业人员意识的提高对市场成长产生了重大影响。世界人口老化和不断上升的压力水平进一步推动了需求，为市场相关人员提供了创新解决方案以满足这些人口统计数据的机会。特别是，个人化医疗和非侵入性递送机制的发展提供了有利的途径。然而，它们受到高昂的药物成本、潜在副作用和严格的监管核准流程的限制，使得市场进入和扩张具有挑战性。此外，传统和非治疗方法的存在治疗方法减少需求。也就是说，对生物製药、生物相似药和数位治疗解决方案的探索，以及针对个体基因谱量身定制的精准医学方法的广泛研究，为我们展示的创新提供了肥沃的土壤。市场的特点是竞争激烈，需要不断的研发来保持竞争优势并满足不断变化的消费者期望。企业应专注于建立策略伙伴关係关係，以获取新技术并开拓开拓的市场，特别是在医疗基础设施不断扩张的新兴国家。此外，您可以透过投资宣传宣传活动，向患者宣传新治疗方法并管理偏头痛诱因。总体而言，保持敏捷性并回应监管变化和技术进步对于应对复杂的市场条件和充分利用成长潜力至关重要。

主要市场统计
基准年[2023] 47.4亿美元
预测年份 [2024] 54.8亿美元
预测年份 [2030] 132.6亿美元
复合年增长率（%） 15.83%

市场动态：揭示快速发展的偏头痛药物市场的关键市场洞察

供需的动态交互作用正在改变偏头痛药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 偏头痛发生率增加和新药上市
    • 女性人口增加和烟草消费量增加
    • 电神经刺激设备等医疗设施的进步
  • 市场限制因素
    • 与偏头痛药物相关的副作用
  • 市场机会
    • 偏头痛药物支持报销政策
    • 增加製药领域的合作和伙伴关係计划
  • 市场挑战
    • 替代疗法的可用性和监管挑战

波特五力：驾驭偏头痛药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对偏头痛药物市场的影响

外部宏观环境因素在塑造偏头痛治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解偏头痛治疗药物市场的竞争状况

对偏头痛治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 偏头痛药物市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估偏头痛治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘偏头痛治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，偏头痛治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 偏头痛发生率增加和新药上市
      • 女性人口增加和烟草消费量增加
      • 电神经刺激设备等医疗设施的进步
    • 抑制因素
      • 与偏头痛药物相关的副作用
    • 机会
      • 偏头痛药物补充报销政策
      • 增加製药领域的合作和伙伴关係计划
    • 任务
      • 替代疗法的可用性和监管挑战
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗层级分類的偏头痛治疗药物市场

  • 抗噁心药
    • 氯丙嗪
    • 甲氧氯普胺
    • 琴酒
  • 抗高血压药
    • Β 受体阻断剂药
    • 钙离子通道阻断剂
  • 麦角
    • Dihydroergotamine
    • 麦角胺
    • 拉斯米迪坦
  • 阿片类药物
    • 奥施康定
    • 哌可赛特
    • 维柯丁
  • 止痛药
    • 阿斯匹灵
    • Ibuprofen
  • 曲普坦
    • Rizatriptan
    • Sumatriptan

第七章依治疗类型分類的偏头痛治疗药物市场

  • 取消
  • 预防

第八章偏头痛治疗药物市场：依给药途径

  • 可注射的
  • 鼻喷剂
  • 口服

第九章 偏头痛治疗药物市场经销商

  • 医院附设药房
  • 网路药房
  • 零售药房

第10章美洲偏头痛药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章：亚太偏头痛药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲偏头痛药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Aegis Therapeutics, LLC
  • Alder Biopharmaceuticals, Inc.
  • Allergan Inc. by AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Biohaven, Ltd
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd
Product Code: MRR-036C5CF3A820

The Migraine Drugs Market was valued at USD 4.74 billion in 2023, expected to reach USD 5.48 billion in 2024, and is projected to grow at a CAGR of 15.83%, to USD 13.26 billion by 2030.

The scope of the migraine drugs market encompasses medications developed to treat acute and chronic migraines, with applications spanning preventive and abortive treatments. This market is driven by the necessity to address a widespread neurological disorder impacting productivity and quality of life globally. Prescription drugs such as triptans, CGRP inhibitors, and over-the-counter medications form a significant part of its application scope, while the end-use spans healthcare settings, pharmacies, and individual patients. The market's growth is majorly influenced by the increasing prevalence of migraines, advancements in drug formulations, and rising awareness amongst patients and healthcare professionals. An aging population and increased stress levels globally further bolster demand, presenting opportunities for market players to innovate solutions catering to these demographics. Notably, personalized medicine and the development of non-invasive delivery mechanisms offer lucrative avenues. However, the market faces limitations due to high drug costs, potential side effects, and stringent regulatory approval processes which pose challenges to market entry and expansion. Furthermore, the presence of traditional and non-medical treatment alternatives can dilute demand. Nevertheless, the exploration of biologic drugs, biosimilars, and digital therapeutic solutions presents fertile ground for innovation, alongside conducting extensive research on precision medicine approaches tailored to individual genetic profiles. The market is characterized by intense competition, necessitating continuous research and development to maintain competitive advantage and meet evolving consumer expectations. Companies should focus on forming strategic partnerships to access new technologies and explore untapped markets, particularly in emerging economies where healthcare infrastructure is expanding. Additionally, investing in awareness campaigns to educate patients about new treatments and managing migraine triggers can enhance market presence. Overall, staying agile and responsive to regulatory shifts and technological advancements will be critical in navigating the complex landscape of the migraine drugs market and harnessing growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 4.74 billion
Estimated Year [2024] USD 5.48 billion
Forecast Year [2030] USD 13.26 billion
CAGR (%) 15.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Migraine Drugs Market

The Migraine Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of migraines and launch of new drugs
    • Rise in female population and increase in cigarette consumption
    • Advancements in healthcare facilities such as electrical nerve stimulation devices
  • Market Restraints
    • Side effects associated with migraine drugs
  • Market Opportunities
    • Supportive reimbursement policies for migraine medications
    • Increased programmes of collaboration and partnership in the pharmaceutical sector
  • Market Challenges
    • Availability of alternative therapies and regulatory challenges

Porter's Five Forces: A Strategic Tool for Navigating the Migraine Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Migraine Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Migraine Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Migraine Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Migraine Drugs Market

A detailed market share analysis in the Migraine Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Migraine Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Migraine Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Migraine Drugs Market

A strategic analysis of the Migraine Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Migraine Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aegis Therapeutics, LLC, Alder Biopharmaceuticals, Inc., Allergan Inc. by AbbVie Inc., Amgen, Inc., AstraZeneca Plc, Biohaven, Ltd, Eisai Co., Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, H. Lundbeck A/S, Johnson & Johnson Services, Inc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, and Teva Pharmaceuticals Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Migraine Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots, Opioid Medication, Pain Reliever, and Triptans. The Anti-Nausea Drug is further studied across Chlorpromazine, Metoclopramide, and Prochlorperazine. The Blood Pressure Lowering Medication is further studied across Beta-Blocker and Calcium Channel Blocker. The Ergots is further studied across Dihydroergotamines, Ergotamine, and Lasmiditan. The Opioid Medication is further studied across OxyContin, Percocet, and Vicodin. The Pain Reliever is further studied across Aspirin and Ibuprofen. The Triptans is further studied across Rizatriptan and Sumatriptan.
  • Based on Treatment Type, market is studied across Abortive and Preventive.
  • Based on Route of Administration, market is studied across Injectable, Nasal Spray, and Oral.
  • Based on Distribution, market is studied across Hospitals Based Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of migraines and launch of new drugs
      • 5.1.1.2. Rise in female population and increase in cigarette consumption
      • 5.1.1.3. Advancements in healthcare facilities such as electrical nerve stimulation devices
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with migraine drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive reimbursement policies for migraine medications
      • 5.1.3.2. Increased programmes of collaboration and partnership in the pharmaceutical sector
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative therapies and regulatory challenges
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Migraine Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Anti-Nausea Drug
    • 6.2.1. Chlorpromazine
    • 6.2.2. Metoclopramide
    • 6.2.3. Prochlorperazine
  • 6.3. Blood Pressure Lowering Medication
    • 6.3.1. Beta-Blocker
    • 6.3.2. Calcium Channel Blocker
  • 6.4. Ergots
    • 6.4.1. Dihydroergotamines
    • 6.4.2. Ergotamine
    • 6.4.3. Lasmiditan
  • 6.5. Opioid Medication
    • 6.5.1. OxyContin
    • 6.5.2. Percocet
    • 6.5.3. Vicodin
  • 6.6. Pain Reliever
    • 6.6.1. Aspirin
    • 6.6.2. Ibuprofen
  • 6.7. Triptans
    • 6.7.1. Rizatriptan
    • 6.7.2. Sumatriptan

7. Migraine Drugs Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Abortive
  • 7.3. Preventive

8. Migraine Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Nasal Spray
  • 8.4. Oral

9. Migraine Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Hospitals Based Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Migraine Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Migraine Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Migraine Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Aegis Therapeutics, LLC
  • 3. Alder Biopharmaceuticals, Inc.
  • 4. Allergan Inc. by AbbVie Inc.
  • 5. Amgen, Inc.
  • 6. AstraZeneca Plc
  • 7. Biohaven, Ltd
  • 8. Eisai Co., Ltd.
  • 9. Eli Lilly and Company
  • 10. Endo International Plc
  • 11. GlaxoSmithKline Plc
  • 12. H. Lundbeck A/S
  • 13. Johnson & Johnson Services, Inc.
  • 14. Merck & Co. Inc.
  • 15. Pfizer Inc.
  • 16. Sanofi SA
  • 17. Teva Pharmaceuticals Industries Ltd

LIST OF FIGURES

  • FIGURE 1. MIGRAINE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. MIGRAINE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MIGRAINE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY VICODIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 330. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 331. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 340. NORWAY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 341. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 350. POLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 351. POLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 352. POLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 353. POLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MIL